---
truth_dimension: orientation
authority_level: advisory
mutation_path: readme_update
---

# Production Use Gap Decomposition - Phase 101

## Scope
Phase 101 is the Production Use Gap Decomposition phase confirmed by roadmap planned-truth surfaces as Phase 101 - Production Use Gap Decomposition.

Phase 101 is audit/planning only.

Phase 101 adds no runtime behavior.

Phase 101 adds no new capability.

Phase 101 does not approve readiness.

Phase 101 does not approve Production Candidate status.

Phase 101 does not approve release-candidate readiness.

Phase 101 does not approve production readiness.

Phase 101 does not approve public usability.

Phase 101 does not implement Phase 102.

Phase 101 does not implement any later phase.

## Evidence rule
Phase 101 counts only committed evidence:

- source files
- tests
- UI behavioral tests
- golden/adversarial tests
- validation logs
- lint gates
- operations docs
- checklists
- roadmap/changelog truth surfaces

Phase 101 does not count roadmap plans as closure, future phase titles as evidence, architecture rationale alone, intended hardening, unmerged or non-history agent runs, speculative safety claims, or prompt intent without committed files.

Roadmap remains planned truth.

`CHANGELOG.md` remains historical truth.

## Decision status model
Each category uses one required status:

| Status | Meaning |
| --- | --- |
| Evidence present, blocker remains | Committed evidence exists, but the category is not sufficient for the relevant human-use stage. |
| Evidence present, conditionally sufficient for current boundary | Committed evidence is sufficient only for Phase 101 audit/planning and current pre-production boundaries. |
| Evidence absent, blocker remains | Committed evidence is missing for the category or only planned evidence exists. |
| Outside current boundary | The category cannot be closed in Phase 101 because it belongs to a later phase or readiness gate. |

## Human-use stage model
Phase 101 separates blockers by human-use stage without approving any stage:

| Stage | Meaning in this audit | Phase 101 posture |
| --- | --- | --- |
| Controlled human trial | A bounded rehearsal or trial with documented operator procedure, non-public scope, and explicit stop conditions. | Not approved. |
| Early human-use candidate | A controlled candidate gate after documentation, transport, provider, persistence, security, deployment, and dry-run evidence. | Not approved. |
| Release candidate | Evidence assembly for release candidacy. | Not approved. |
| Production Candidate | Production Candidate status reassessment. | Not approved. |
| Public/general use | Public or general availability. | Not approved. |

## Human operator workflow and role clarity
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Phase 98 operations documentation describes local startup, validation, outputs, troubleshooting, rollback expectations, and operator limits; the README describes human review as a project goal; roadmap planned truth names Phase 102 as Human Operator Workflow Contract. |
| Remaining blockers | Operator roles, handoff states, expected review states, escalation/stop responsibilities, trial participant boundaries, and role-specific failure decisions are not yet a committed workflow contract. |
| Required future evidence | A committed human operator workflow contract with role definitions, permitted actions, prohibited actions, expected states, evidence handoffs, and stop conditions. |
| Likely phase dependency | Phase 102 - Human Operator Workflow Contract. |
| Stop condition | Stop before controlled human trial if role ownership, operator authority limits, or state transitions are ambiguous. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## UI runtime review surface activation
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | UI behavioral tests cover the current submission boundary, malformed input, spoofed capability text, risky text, and bridge non-call expectations; Phase 100 treats current UI coverage as only current-boundary evidence. |
| Remaining blockers | The browser runtime review surface is not activated as a human operator review experience for trial use; current tests show non-live/non-authoritative behavior rather than an active runtime review surface. |
| Required future evidence | UI review surface activation evidence, UI behavioral tests for activated review states, and proof that activation remains review-only and cannot mutate Rust-owned authority. |
| Likely phase dependency | Phase 103 - UI Runtime Review Surface Activation Boundary, after Phase 102. |
| Stop condition | Stop before any human-facing runtime review if the UI cannot show expected states, warnings, review outputs, and non-authority posture. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## UI-to-Rust local transport
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current committed source and tests preserve a non-live UI submission boundary; Phase 91/Phase 100 evidence documents transport spoofing hardening for the pre-bridge boundary. |
| Remaining blockers | No committed live local UI-to-Rust transport prototype exists for human trial use. Existing evidence is negative/non-live, not an operational local bridge. |
| Required future evidence | A local, non-public UI-to-Rust transport prototype with explicit Rust authority boundaries, request/response contracts, local-only constraints, failure modes, and tests. |
| Likely phase dependency | Phase 104 - UI-to-Rust Local Transport Prototype Boundary, after Phase 103. |
| Stop condition | Stop before live bridge use if transport locality, authentication/intent shape, replay handling, non-authority limits, or error states are not testable. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Transport abuse hardening for live local bridge
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current adversarial and UI behavioral tests cover spoofing, authority injection text, disabled execution flags, and non-live bridge expectations for the existing boundary. |
| Remaining blockers | Live-bridge abuse cases cannot be closed until a concrete live local bridge exists. Current hardening does not prove malformed, spoofed, replayed, hostile, or high-volume behavior against a live transport surface. |
| Required future evidence | Negative-path tests and operations evidence for the live local bridge, including malformed requests, replay attempts, spoofed identity/capability claims, hostile payloads, and failure isolation. |
| Likely phase dependency | Phase 105 - Transport Abuse Hardening for Live Local Bridge, after Phase 104. |
| Stop condition | Stop before controlled human trial if live bridge abuse tests are absent or if failures can mutate authority, bypass review, or mask validation failures. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Provider configuration contract
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current Rust source and tests treat provider output as untrusted harness evidence, and Phase 100 documents provider output as untrusted for the current local harness. |
| Remaining blockers | No committed provider configuration contract defines provider selection, secret handling, offline/online mode, operator consent, configuration validation, or failure states for live provider use. |
| Required future evidence | A committed provider configuration contract and validation evidence showing provider intent/configuration only, without live provider execution. |
| Likely phase dependency | Phase 106 - Provider Configuration Contract. |
| Stop condition | Stop before provider execution if configuration provenance, secret boundaries, operator consent, disabled states, or provider selection are ambiguous. |
| Human-use blocker | Blocks controlled human trial if trial includes provider use; blocks early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Provider execution sandbox
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Adversarial and integration tests show provider-shaped text remains untrusted and non-authoritative in the current harness. |
| Remaining blockers | No committed sandboxed provider execution exists. There is no evidence for network/process isolation, execution containment, secret minimization, output quarantine, or sandbox failure behavior. |
| Required future evidence | Sandboxed provider execution evidence with tests proving provider output remains untrusted and cannot mutate authority, persistence, recovery, replay, action, or UI trust state. |
| Likely phase dependency | Phase 107 - Provider Execution Sandbox, after Phase 106. |
| Stop condition | Stop before human trial with live providers if provider execution is not bounded, observable, and fail-closed. |
| Human-use blocker | Blocks controlled human trial with provider execution, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Provider timeout and resource limits
**Decision status:** Evidence absent, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current evidence does not establish live provider timeout/resource enforcement because provider execution is not active. |
| Remaining blockers | Timeout, cancellation, retry, resource budget, output size, and failure classification behavior for live providers is not committed. |
| Required future evidence | Tests and operations evidence for provider timeout, cancellation, retry limits, output bounds, resource ceilings, and failure reporting. |
| Likely phase dependency | Phase 108 - Provider Timeout and Resource Limit Enforcement, after Phase 107. |
| Stop condition | Stop before live-provider human trial if provider calls can hang, exceed resource budgets, retry unsafely, or mask failure. |
| Human-use blocker | Blocks controlled human trial with provider execution, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Durable persistence authority
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Existing persistence APIs, integration tests, export evidence, recovery candidate tests, and Phase 100 audit evidence document current persistence-like boundaries and non-authority constraints. |
| Remaining blockers | Current evidence does not decide whether durable persistence should become authoritative for human use, what authority it may hold, or which durability guarantees are mandatory. |
| Required future evidence | A committed persistence authority decision/audit with permitted authority, prohibited authority, data lifecycle, corruption handling, durability expectations, and rollback implications. |
| Likely phase dependency | Phase 109 - Durable Persistence Authority Decision. |
| Stop condition | Stop before persistence activation if authority ownership, durability semantics, auditability, or rollback behavior is undecided. |
| Human-use blocker | Blocks early human-use candidate, release candidate, Production Candidate, and public/general use; may block controlled human trial if trial requires durable state. |

## Authoritative persistence activation
**Decision status:** Outside current boundary.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current committed evidence shows bounded export/persistence/recovery surfaces but not activated authoritative persistence. |
| Remaining blockers | Activation cannot be assessed before the authority decision is committed. |
| Required future evidence | Narrow activation evidence, tests, validation logs, and operations documentation proving only the authority permitted by Phase 109 is active. |
| Likely phase dependency | Phase 110 - Authoritative Persistence Activation, after Phase 109. |
| Stop condition | Stop before activation if implementation exceeds Phase 109 authority or if data writes are not auditable and recoverable. |
| Human-use blocker | Blocks early human-use candidate, release candidate, Production Candidate, and public/general use; may block controlled human trial if durable authority is required. |

## Recovery lifecycle hardening
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Existing source and tests cover recovery candidate preparation, mismatch rejection, in-memory acceptance limits, non-persistence, non-append, non-repair, and non-promotion for the current boundary. |
| Remaining blockers | Recovery lifecycle hardening under the future persistence posture is not complete; no evidence covers recovery operations after authoritative persistence activation. |
| Required future evidence | Recovery lifecycle tests and docs for future persistence posture, including explicit recovery states, no silent recovery, no silent repair, replay consistency, operator confirmation, and audit trails. |
| Likely phase dependency | Phase 111 - Recovery Lifecycle Hardening, after Phases 109-110. |
| Stop condition | Stop before durable human-use trials if recovery can silently promote, repair, replace, or obscure state. |
| Human-use blocker | Blocks early human-use candidate, release candidate, Production Candidate, and public/general use; may block controlled human trial with durable state. |

## Policy versioning and governance evidence
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Governance docs, roadmap/changelog truth surfaces, checklists, schemas, validation gates, and operations docs provide current authority/truth posture. |
| Remaining blockers | Policy/governance evidence is not yet versioned for deployment/trial attribution across future transport, provider, persistence, and security gates. |
| Required future evidence | Versioned policy/governance evidence references tied to runtime/configuration evidence without rewriting governance authority. |
| Likely phase dependency | Phase 112 - Policy Versioning and Governance Evidence. |
| Stop condition | Stop before deployment/trial evidence assembly if policy versions, governance references, or evidence provenance cannot be attributed. |
| Human-use blocker | Blocks early human-use candidate, release candidate, Production Candidate, and public/general use; may block controlled human trial if trial evidence attribution is required. |

## Deployment configuration
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Phase 96-99 operations docs define local startup, packaging boundaries, troubleshooting, release dry-run mechanics, and non-approval posture. |
| Remaining blockers | No committed deployment configuration contract defines environment variables, local paths, ports, secrets, feature flags, update behavior, or rollback configuration for a deployment candidate. |
| Required future evidence | Deployment configuration documentation and validation proving local, bounded, non-public deployment posture without release automation or public distribution. |
| Likely phase dependency | Phase 113 - Deployment Configuration. |
| Stop condition | Stop before a local deployment candidate if configuration is implicit, undocumented, or not reproducible. |
| Human-use blocker | Blocks controlled human trial if a deployment candidate is needed; blocks early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Local deployment candidate
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current local startup/build/dry-run docs and validation gates support local operator mechanics only; Phase 99 dry run explicitly did not publish or approve release readiness. |
| Remaining blockers | No committed local deployment candidate is defined with complete artifact inventory, configuration, execution boundary, rollback, and non-public restrictions. |
| Required future evidence | A local deployment candidate boundary with reproducible commands, artifact inventory, excluded artifacts, validation logs, rollback instructions, and non-public constraints. |
| Likely phase dependency | Phase 114 - Local Deployment Candidate, after Phase 113. |
| Stop condition | Stop before controlled human trial if there is no reproducible candidate target and rollback path. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Security threat model and abuse-case audit
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Existing hardening phases and adversarial tests cover several abuse classes for the current pre-live boundary. |
| Remaining blockers | No committed security threat model covers the future combined local bridge, provider execution, persistence authority, deployment configuration, recovery lifecycle, and human trial procedure. |
| Required future evidence | Security threat model and abuse-case audit with trust boundaries, attacker goals, residual risks, mitigations, and gate decisions. |
| Likely phase dependency | Phase 115 - Security Threat Model and Abuse-Case Audit, after local deployment candidate definition. |
| Stop condition | Stop before human trial if security threats and abuse cases for active surfaces are not reviewed and documented. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Operator documentation for controlled human trial
**Decision status:** Evidence present, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Phase 98 operator documentation covers local startup/troubleshooting for the existing boundary. |
| Remaining blockers | Controlled human trial documentation is not committed: participant scope, consent/limits, trial scripts, expected observations, stop rules, escalation contacts, evidence capture, and rollback criteria remain absent. |
| Required future evidence | Controlled human trial operator documentation aligned with workflow, deployment, security, transport, provider, persistence, and recovery evidence. |
| Likely phase dependency | Phase 116 - Operator Documentation for Controlled Human Trial, after Phase 115. |
| Stop condition | Stop before trial if operators cannot follow a bounded procedure or identify stop/escalation conditions. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Human trial dry run
**Decision status:** Evidence absent, blocker remains.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | No committed controlled human trial dry-run evidence exists. Phase 99 release engineering dry run is not a human trial dry run. |
| Remaining blockers | Trial procedure fidelity, evidence capture, rollback, escalation, stop-condition behavior, and non-public boundary have not been rehearsed. |
| Required future evidence | Dry-run logs/checklist evidence showing the controlled human trial procedure can be executed without public availability or readiness approval. |
| Likely phase dependency | Phase 117 - Human Trial Dry Run, after Phase 116. |
| Stop condition | Stop before real controlled trial if dry-run evidence is absent, incomplete, or indicates masked failure. |
| Human-use blocker | Blocks controlled human trial, early human-use candidate, release candidate, Production Candidate, and public/general use. |

## Release-candidate evidence assembly
**Decision status:** Outside current boundary.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Release checklist and Phase 99 dry-run docs provide mechanics and non-approval posture only. |
| Remaining blockers | Release-candidate evidence cannot be assembled until prior workflow, UI, transport, provider, persistence, recovery, governance, deployment, security, and trial dry-run evidence exists. |
| Required future evidence | Release-candidate evidence bundle/checklist with validation logs, artifact inventory, source/test/lint evidence, risk notes, and explicit non-automatic approval posture. |
| Likely phase dependency | Phase 118 - Release-Candidate Evidence Assembly. |
| Stop condition | Stop before release candidate if any prerequisite gate is missing or evidence assembly contains readiness claims without approval. |
| Human-use blocker | Blocks release candidate, Production Candidate, and public/general use; not sufficient for controlled human trial by itself. |

## Production Candidate reassessment
**Decision status:** Outside current boundary.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Phase 100 concluded Production Candidate status is not approved and recommended further decomposition. |
| Remaining blockers | Production Candidate reassessment cannot occur until release-candidate evidence and prior human-use blockers are addressed. |
| Required future evidence | A committed reassessment decision gate that evaluates all prior evidence and records approval or non-approval without relying on roadmap plans. |
| Likely phase dependency | Phase 119 - Production Candidate Reassessment. |
| Stop condition | Stop before Production Candidate status if release-candidate evidence is missing, stale, incomplete, or contaminated by approval assumptions. |
| Human-use blocker | Blocks Production Candidate and public/general use. |

## Early controlled human-use gate
**Decision status:** Outside current boundary.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | No committed early controlled human-use gate evidence exists; the roadmap names Phase 120 as a later planned gate only. |
| Remaining blockers | Controlled human-use candidacy cannot be decided before workflow, UI, transport, provider, persistence, recovery, governance, deployment, security, trial dry-run, release-candidate evidence, and Production Candidate reassessment work. |
| Required future evidence | A committed early controlled human-use gate decision with scope, participants, safeguards, residual risk acceptance, stop conditions, monitoring, rollback, and explicit non-public boundary. |
| Likely phase dependency | Phase 120 - Early Controlled Human-Use Candidate Gate. |
| Stop condition | Stop before controlled early human use if any prerequisite is missing or if public/general-use claims appear. |
| Human-use blocker | Blocks early human-use candidate and public/general use; does not approve release candidate or Production Candidate status by itself. |

## Public/general use blockers
**Decision status:** Outside current boundary.

| Required field | Phase 101 finding |
| --- | --- |
| Current committed evidence | Current committed evidence repeatedly states public usability is not approved. |
| Remaining blockers | Public/general use requires all earlier gates plus additional public distribution, support, monitoring, update, security, privacy, abuse response, documentation, and operational readiness evidence that is not present. |
| Required future evidence | A separate public/general-use readiness gate with public distribution authority, support model, monitoring/incident response, update policy, security review, privacy posture, and explicit approval record. |
| Likely phase dependency | Later than Phase 120; not implemented or approved by Phase 101. |
| Stop condition | Stop before public/general use until a dedicated public/general-use approval gate exists and all earlier gates are closed. |
| Human-use blocker | Blocks public/general use. |

## Dependency order
1. Phase 101 - Production Use Gap Decomposition.
2. Phase 102 - Human Operator Workflow Contract.
3. Phase 103 - UI Runtime Review Surface Activation Boundary.
4. Phase 104 - UI-to-Rust Local Transport Prototype Boundary.
5. Phase 105 - Transport Abuse Hardening for Live Local Bridge.
6. Phase 106 - Provider Configuration Contract.
7. Phase 107 - Provider Execution Sandbox.
8. Phase 108 - Provider Timeout and Resource Limit Enforcement.
9. Phase 109 - Durable Persistence Authority Decision.
10. Phase 110 - Authoritative Persistence Activation.
11. Phase 111 - Recovery Lifecycle Hardening.
12. Phase 112 - Policy Versioning and Governance Evidence.
13. Phase 113 - Deployment Configuration.
14. Phase 114 - Local Deployment Candidate.
15. Phase 115 - Security Threat Model and Abuse-Case Audit.
16. Phase 116 - Operator Documentation for Controlled Human Trial.
17. Phase 117 - Human Trial Dry Run.
18. Phase 118 - Release-Candidate Evidence Assembly.
19. Phase 119 - Production Candidate Reassessment.
20. Phase 120 - Early Controlled Human-Use Candidate Gate.
21. Public/general use requires a later explicit gate outside Phase 101.

This dependency order is advisory decomposition from committed evidence and roadmap planned truth. It does not close any blocker by naming the order.

## Stop conditions
| Stop condition | Applies before |
| --- | --- |
| Operator workflow roles or expected states are ambiguous. | Phase 103 and controlled human trial. |
| UI review surface cannot show review-only state or warnings. | Live local bridge and controlled human trial. |
| Local transport is not demonstrably local, bounded, and non-authoritative. | Controlled human trial. |
| Live transport abuse tests are absent. | Controlled human trial. |
| Provider configuration lacks explicit secret, consent, disabled-mode, and selection rules. | Provider execution. |
| Provider execution is not sandboxed and fail-closed. | Provider-backed trial. |
| Provider timeouts/resource limits are absent. | Provider-backed trial. |
| Persistence authority is undecided. | Authoritative persistence activation. |
| Persistence activation exceeds decided authority. | Durable human-use trial. |
| Recovery can silently promote, repair, replace, or obscure state. | Durable human-use trial. |
| Policy/governance evidence cannot be version-attributed. | Deployment/trial evidence assembly. |
| Deployment configuration is implicit or unreproducible. | Local deployment candidate. |
| Security threat model is absent for active surfaces. | Controlled human trial. |
| Controlled human trial documentation is absent. | Human trial dry run. |
| Human trial dry run is absent or shows masked failure. | Controlled human trial. |
| Release-candidate evidence is incomplete. | Release candidate. |
| Production Candidate reassessment evidence is incomplete. | Production Candidate. |
| Early controlled human-use gate is incomplete. | Early human-use candidate. |
| Public/general-use approval gate is absent. | Public/general use. |

## Phase 102 gate decision
Phase 102 may begin only as the next planned documentation/contract phase: Human Operator Workflow Contract.

This Phase 102 recommendation is not readiness approval.

Phase 102, if recommended, is the next planned documentation/contract phase only.

Phase 101 does not implement Phase 102.

## Production Candidate status
Production Candidate status: not approved.

production human use is not approved.

Phase 101 does not approve Production Candidate status.

## Release-candidate readiness status
release-candidate readiness: not approved.

Phase 101 does not approve release-candidate readiness.

## Public/general use status
public usability: not approved.

public/general use is not approved.

production readiness: not approved.

Phase 101 does not approve public usability.

## Roadmap/changelog truth posture
Roadmap remains planned truth.

`CHANGELOG.md` remains historical truth.

Future phase titles are dependency labels, not evidence of completion.

Phase 101 records the decomposition in this advisory operations document and historical completion in `CHANGELOG.md` only after validation and commit.

## Required follow-ups
| Follow-up | Required before | Status in Phase 101 |
| --- | --- | --- |
| Human Operator Workflow Contract | UI activation and controlled human trial | Recommended as Phase 102; not readiness approval. |
| UI runtime review activation evidence | Live local bridge and controlled human trial | Blocker remains. |
| UI-to-Rust local transport prototype | Transport hardening and controlled human trial | Blocker remains. |
| Live transport abuse hardening | Controlled human trial | Blocker remains. |
| Provider configuration, sandbox, timeout/resource evidence | Provider-backed trial and broader readiness | Blocker remains. |
| Persistence authority decision and activation evidence | Durable human-use trial | Blocker remains. |
| Recovery lifecycle hardening | Durable human-use trial | Blocker remains. |
| Policy/governance versioning | Deployment/trial evidence attribution | Blocker remains. |
| Deployment configuration and local deployment candidate | Controlled human trial | Blocker remains. |
| Security threat model and abuse-case audit | Controlled human trial | Blocker remains. |
| Controlled human trial documentation and dry run | Controlled human trial | Blocker remains. |
| Release-candidate evidence assembly | Release candidate | Outside current boundary. |
| Production Candidate reassessment | Production Candidate | Outside current boundary. |
| Early controlled human-use gate | Early human-use candidate | Outside current boundary. |
| Public/general-use gate | Public/general use | Outside current boundary. |

## Deferred items
| Item | Reason |
| --- | --- |
| Runtime behavior | Phase 101 is audit/planning only. |
| New capability | Phase 101 adds no new capability. |
| Rust source changes | Disallowed by Phase 101 surface discipline. |
| TypeScript source changes | Disallowed by Phase 101 surface discipline. |
| Tests, scripts, workflows, package files, README, AGENTS, schemas, governance docs, and architecture docs | Disallowed by Phase 101 surface discipline. |
| Release artifacts | Phase 101 creates no release artifacts. |
| Release-candidate readiness approval | Not approved. |
| Production Candidate approval | Not approved. |
| Production readiness approval | Not approved. |
| Public usability approval | Not approved. |
| Phase 102 implementation | Not implemented in Phase 101. |

## Confirmed vs suspected
### Confirmed
- Phase 101 is audit/planning only.
- Phase 101 adds no runtime behavior.
- Phase 101 adds no new capability.
- Phase 101 does not approve readiness.
- Phase 101 does not approve Production Candidate status.
- Phase 101 does not approve release-candidate readiness.
- Phase 101 does not approve production readiness.
- Phase 101 does not approve public usability.
- Phase 101 does not implement Phase 102.
- Phase 102 may begin only as the next planned documentation/contract phase if accepted by the project.
- Phase 102 recommendation is not readiness approval.
- Roadmap remains planned truth.
- `CHANGELOG.md` remains historical truth.
- Current committed evidence supports decomposition, not closure of production human-use blockers.

### Suspected
- None. Suspected items are not counted as evidence in Phase 101.

## Non-readiness statement
Phase 101 is audit/planning only and records a production-use gap decomposition.

Phase 101 adds no runtime behavior and no new capability.

Phase 101 does not approve readiness, Production Candidate status, release-candidate readiness, production readiness, public usability, production human use, public/general use, or Phase 102 implementation.
